Maravai LifeSciences Holdings Inc

MRVI remains in a clear Stage 2 advance with higher highs and higher lows supported by rising EMAs and constructive volume. However, price is extended well above the 9/21/50 EMA zone and in extreme overbought conditions, making immediate entry unfavorable. Medium-term bias stays bullish, underpinned by the active Parabola acceleration and intact trend structure, yet heightened exhaustion risk demands patience. Short-term execution should be deferred into pullbacks or consolidation around the rising EMA support area. Primary risks include abrupt reversals from extreme overbought levels and a Stage 2→3 transition if EMAs fail to hold.

• ↑Q1 2026 revenue $65.8M (+41% YoY), TriLink up 65%.
• ↑Free cash flow $4.2M positive, first since Q3 2024.
• ↓Negative earnings yield and weak profitability factors persist.